Concord Biotech Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹247Cr
- −20.3% YoY
- +21.1% QoQ
- Net profit
- ₹63Cr
- −36.4% YoY
- +46.5% QoQ
- Margin
- 37%
- −7 pp YoY
- +7 pp QoQ
Guidance rank: #74 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Expected stronger revenue performance in H2 FY26 compared to H2 FY25, with growth anticipated to recover from timing-related setbacks. Concord Biotech anticipates a 25% CAGR driven by: - Capacity ramp-up in injectable units. - Growth in CDMO (Contract Development and Manufacturing Organization) business. - H2 FY26 expected to show better growth compared to H2 FY25, though exact magnitude is uncertain due to external factors. - Temporary issues (EU approval delays, Middle East contract deferment, U.S.
From Concord Biotech Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Expected stronger revenue performance in H2 FY26 compared to H2 FY25, with growth anticipated to recover from timing-related setbacks.
- Long-term target to achieve a 25% CAGR supported by new facilities, expanded product mix, and ramping up of injectable and CDMO businesses.
- Injectable facility commercialization progressing; revenues to pick up from India market initially, followed by emerging markets after 12-18 months.
- Recovery of deferred revenues from EU and Middle East contracts expected in coming quarters, mitigating recent declines.
- Positive traction in second-source opportunities and ongoing CDMO projects expected to contribute to future growth.
2 more points from Concord Biotech Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- It highlights the commissioning of a new injectable facility in March, indicating recent capital investment.
- The injectable facility is expected to ramp up commercial activity, targeting the Indian market initially, and expanding to emerging markets after 12-18 months.
- Development work in CAR-T cell therapy is underway, focusing on development for 12-15 months, which suggests ongoing R&D investment.
2 more points from Concord Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Currently, Concord Biotech has one commercial CDMO project underway with sales having started and progressing well.
- Additional CDMO projects have been commercialized but are relatively small and in initial stages, serving as inroads to build larger relationships with global MNC clients.
- Discussions are ongoing with two potential innovator companies for CDMO opportunities; one was temporarily on hold due to external tariff issues but has now resumed with renewed engagement.
- Visibility on full-year CDMO revenues and orderbook clarity is expected next year as products launch and ramp-up occurs.
2 more points from Concord Biotech Ltd's call on order book
Create a free account to keep reading this call
Concord Biotech Ltd — Quarterly revenue & net profit
Concord Biotech Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 247 | 310 | -20.3% | 204 | +21.1% |
| Operating profit (EBITDA) | 91 | 137 | -33.6% | 61 | +49.2% |
| Operating margin | 37% | 44% | -7 pp | 30% | +7 pp |
| Profit before tax | 86 | 133 | -35.3% | 57 | +50.9% |
| Net profit (PAT) | 63 | 99 | -36.4% | 43 | +46.5% |
| EPS (₹) | 3.01 | 4.72 | -36.2% | 2.03 | +48.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹312 Cr, net profit ₹76 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Concord Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Concord Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Concord Biotech Ltd Q2 FY26 results?
Expected stronger revenue performance in H2 FY26 compared to H2 FY25, with growth anticipated to recover from timing-related setbacks. Concord Biotech anticipates a 25% CAGR driven by: - Capacity ramp-up in injectable units. - Growth in CDMO (Contract Development and Manufacturing Organization) business. - H2 FY26 expected to show better growth compared to H2 FY25, though exact magnitude is uncertain due to external factors. - Temporary issues (EU approval delays, Middle East contract deferment, U.S.
What is Concord Biotech Ltd share price analysis?
Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹14,489 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
